Lonza’s Post

Enhancing the stability of delivery systems is high on the priority list of those discovering and developing the next wave of mRNA therapeutics. This Expert Insight from Jin Zhai, Trystin Cote, and Yupeng Chen examines the mechanisms of mRNA delivery system degradation and explores potential pathways to improvement. https://lnkd.in/gaGj8ve9

Promise of personalized cancer vaccines through the inherent nimbleness of #mRNA platform. Full podcast here: https://lnkd.in/e5fRneGk From a manufacturers point of view how best to automate, miniaturize and speed up performance? Kate Broderick and Tom Madden also consider pandemic preparedness, scientific messaging to the general public, and, interestingly, combining the mRNA platform with other emerging modalities and traditional approaches such as monoclonal antibody delivery. #mrnavaccines #oncology #pandemicpreparedness #rnatherapeutics #crispr Thanks also to Acuitas Therapeutics TriLink BioTechnologies, part of Maravai LifeSciences and Pharmaceutical Technology

💬💡 We spoke with Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer at Genmab, about the company’s key achievements and its focus on innovative solutions in antibody therapeutics! Since its establishment in 1999, Genmab has not only expanded its reach globally but has also spearheaded transformative therapies that have redefined cancer treatment and addressed other critical illnesses. ➡️ Read the full interview with Tahi Ahmadi to learn more about Genmab's strategic vision, technological advancements, and the next frontier in antibody research: https://buff.ly/4bcg368 #ClinicalTrials #Antibodies #Antibody #Biologics #ClinicalResearch #Biologic #ProteinTherapeutic #AntibodyDrug

We aim to deliver the most innovative, treatment-directing testing possible while providing analytical approaches that lead the way for personalised medicine and translational science. At Pierian Biosciences we have implemented 2 platforms to aid in the testing, analysis, and evaluation of tumour samples. ImmunoINTEL - a flow cytometry-based platform providing phenotypic characterisation and quantitative functional interrogation of tumour and immune populations within a tumour sample and relevant tissue. ChemoINTEL - is a functional multi-parametric chemo-sensitivity assay measuring the real-time kinetic molecular and morphologic apoptotic response in isolated tumour cells (dissociated solid tumours or hematologic cancers) induced by cytotoxic agents, targeted molecular therapeutics, biologics, or combination therapy. Pierian Biosciences is dedicated to providing clinically actionable diagnostic information enabling healthcare providers to personalise treatment of patients with cancer and auto-immune disease. #chemotherapy #immunotherapy #cancerresearch #bioscience #healthcare

This free to download Article Collection aims to offer scientists a wealth of information on monoclonal antibody (mAb) therapy, enabling you to advance your research in this field. Monoclonal antibody therapy has revolutionized treatment for diseases like cancer, offering personalized options with fewer side effects. Antibody-drug conjugates combine the precision of mAbs with chemotherapy’s toxicity, targeting specific cells effectively. Both ADCs and mAbs play crucial roles in fighting diseases, extending beyond oncology to include autoimmune diseases and infections. We hope that researchers will find this collection of articles useful in their pursuit of knowledge about the latest developments in the field of biopharmaceutical drug research and manufacturing, specifically regarding monoclonal antibodies (mAbs) and antibody-drug conjugates, as well as in precision medicine. ➡️https://ow.ly/4sC150Sn2ih #WileyAnalyticalScience #CurrentProtocols #Cytiva #mAbs #antibodies #PAT #ADAC #HTS #purification

Aragen is excited to be participating at the 7th Annual AFDD Summit, scheduled from October 24-26, 2023 in Boston, MA. Join us to discover Aragen portfolio in fibrosis research. Aragen has a portfolio of in vivo fibrosis models and world class expertise to support clients in the development of anti-fibrotic therapeutic or prophylactic candidates. In hundreds of studies, over the course of more than a decade, we have evaluated the efficacy of test compounds spanning several modalities (small molecules, biologics, RNA therapeutics, exosomes etc.) on a variety of assay platforms, ultimately resulting in INDs for our clients. Our diet-induced, chemical-induced and surgical models of fibrosis, coupled with an extensive evaluation of disease biomarkers, as well as cellular and molecular mechanisms, can help drive research efforts towards finding novel therapies.   What we bring:   ◉ 75+ years of combined fibrosis research experience ◉ 600+ successful fibrosis studies for 50+ clients ◉ 11 programs in clinical development, many in phase II   To learn more about our fibrosis solutions visit https://lnkd.in/g45Spi3m or write to us at [email protected] to schedule meeting with our experts. #AFDDSummit #FibrosisResearch #DrugDiscovery #Development #Boston #MA #USA #AragenInnovation

Step into the future of mRNA screening with 3D bioprinting! Accelerate your #mRNA research with 3D bioprinted in vitro models. Learn how our TissueFab® bioinks can serve as a testbed for new mRNA therapeutics. #mRNA #3DBioprinting

https://lnkd.in/dFvswtta Key Insights: • Under the extended agreement, Mainz Biomed will utilize Liquid Biosciences' EMERGE platform for the analysis of its eAArly DETECT and ReconAAsense studies. The collaborative effort aims to advance the development of self-administrable cancer detection products Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #ai #artificialintelligence #partners #HealthcareAnalytics #NewsUpdate #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights